{"id":44590,"date":"2025-10-27T21:56:41","date_gmt":"2025-10-27T13:56:41","guid":{"rendered":"https:\/\/flcube.com\/?p=44590"},"modified":"2025-10-27T21:56:42","modified_gmt":"2025-10-27T13:56:42","slug":"sunshine-guojian-reports-strong-q3-growth-and-advances-key-rd-programs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44590","title":{"rendered":"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&amp;D Programs"},"content":{"rendered":"\n<p>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688336:SHA\">SHA: 688336<\/a>), a China-based company, released its 2025 third-quarter report on October 24, 2025. In the first three quarters of 2025, the company achieved an operating revenue of RMB 1.116 billion, representing a year-on-year (YOY) increase of 18.80%. Net profit attributable to the parent company reached RMB 399 million, marking a substantial YOY growth of 71.15%.<\/p>\n\n\n\n<p><strong>R&amp;D Progress<\/strong><br>By the end of the third quarter of 2025, Sunshine Guojian reported significant R&amp;D advancements:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Anti-IL-17A mAb (608):<\/strong> NDA accepted for moderate-to-severe plaque psoriasis; Phase III trial for Ankylosing Spondylitis ongoing; Phase II trial for non-radiographic axial spondyloarthritis achieved positive results.<\/li>\n\n\n\n<li><strong>Anti-IL-5 mAb (610):<\/strong> Phase III trial for severe eosinophilic asthma ongoing; Phase II trial for extended dosing interval in adults ongoing.<\/li>\n\n\n\n<li><strong>Anti-IL-4R\u03b1 mAb (611):<\/strong> Phase III trial for moderate-to-severe atopic dermatitis met primary endpoint; Phase III trial for chronic rhinosinusitis with nasal polyps completed; Phase III trial for COPD ongoing.<\/li>\n\n\n\n<li><strong>Recombinant Anti-IL-1\u03b2 mAb (613):<\/strong> NDA submitted and accepted for acute gouty arthritis; Phase II study for intercritical gouty arthritis completed with positive results.<\/li>\n\n\n\n<li><strong>Recombinant Anti-BDCA2 mAb (626):<\/strong> Phase Ib\/II trial for Systemic Lupus Erythematosus (SLE) underway.<\/li>\n\n\n\n<li><strong>Recombinant Anti-TL1A mAb (627):<\/strong> Phase I trial for Ulcerative Colitis (UC) underway.<\/li>\n<\/ul>\n\n\n\n<p><strong>Partnership Highlight<\/strong><br>In July 2025, 3SBio Sunshine Guojian and 3SBio signed an exclusive licensing agreement with Pfizer, granting Pfizer global development and commercialization rights for SSGJ-707. The deal included a USD 1.4 billion upfront payment, setting a new record for Chinese innovative drug out-licensing transactions, with a total potential value exceeding USD 6 billion.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/H2_AN202510231767584472_1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of H2_AN202510231767584472_1.\"><\/object><a id=\"wp-block-file--media-b0bcf2af-abd8-44ab-bb3e-d19d3778dc95\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/H2_AN202510231767584472_1.pdf\">H2_AN202510231767584472_1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/H2_AN202510231767584472_1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b0bcf2af-abd8-44ab-bb3e-d19d3778dc95\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a China-based company, released its 2025 third-quarter&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44593,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,1553,398],"class_list":["post-44590","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-sha-688336","tag-sunshine-guojian-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&amp;D Programs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a China-based company, released its 2025 third-quarter report on October 24, 2025. In the first three quarters of 2025, the company achieved an operating revenue of RMB 1.116 billion, representing a year-on-year (YOY) increase of 18.80%. Net profit attributable to the parent company reached RMB 399 million, marking a substantial YOY growth of 71.15%.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44590\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&amp;D Programs\" \/>\n<meta property=\"og:description\" content=\"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a China-based company, released its 2025 third-quarter report on October 24, 2025. In the first three quarters of 2025, the company achieved an operating revenue of RMB 1.116 billion, representing a year-on-year (YOY) increase of 18.80%. Net profit attributable to the parent company reached RMB 399 million, marking a substantial YOY growth of 71.15%.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44590\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T13:56:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-27T13:56:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2706.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44590#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44590\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&amp;D Programs\",\"datePublished\":\"2025-10-27T13:56:41+00:00\",\"dateModified\":\"2025-10-27T13:56:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44590\"},\"wordCount\":266,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44590#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2706.webp\",\"keywords\":[\"Finanical Reports\",\"SHA: 688336\",\"Sunshine Guojian Pharmaceutical\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44590#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44590\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44590\",\"name\":\"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&amp;D Programs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44590#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44590#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2706.webp\",\"datePublished\":\"2025-10-27T13:56:41+00:00\",\"dateModified\":\"2025-10-27T13:56:42+00:00\",\"description\":\"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a China-based company, released its 2025 third-quarter report on October 24, 2025. In the first three quarters of 2025, the company achieved an operating revenue of RMB 1.116 billion, representing a year-on-year (YOY) increase of 18.80%. Net profit attributable to the parent company reached RMB 399 million, marking a substantial YOY growth of 71.15%.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44590#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44590\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44590#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2706.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2706.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&D Programs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44590#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&amp;D Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&amp;D Programs - Insight, China&#039;s Pharmaceutical Industry","description":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a China-based company, released its 2025 third-quarter report on October 24, 2025. In the first three quarters of 2025, the company achieved an operating revenue of RMB 1.116 billion, representing a year-on-year (YOY) increase of 18.80%. Net profit attributable to the parent company reached RMB 399 million, marking a substantial YOY growth of 71.15%.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44590","og_locale":"en_US","og_type":"article","og_title":"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&amp;D Programs","og_description":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a China-based company, released its 2025 third-quarter report on October 24, 2025. In the first three quarters of 2025, the company achieved an operating revenue of RMB 1.116 billion, representing a year-on-year (YOY) increase of 18.80%. Net profit attributable to the parent company reached RMB 399 million, marking a substantial YOY growth of 71.15%.","og_url":"https:\/\/flcube.com\/?p=44590","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-27T13:56:41+00:00","article_modified_time":"2025-10-27T13:56:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2706.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44590#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44590"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&amp;D Programs","datePublished":"2025-10-27T13:56:41+00:00","dateModified":"2025-10-27T13:56:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44590"},"wordCount":266,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44590#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2706.webp","keywords":["Finanical Reports","SHA: 688336","Sunshine Guojian Pharmaceutical"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44590#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44590","url":"https:\/\/flcube.com\/?p=44590","name":"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&amp;D Programs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44590#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44590#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2706.webp","datePublished":"2025-10-27T13:56:41+00:00","dateModified":"2025-10-27T13:56:42+00:00","description":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a China-based company, released its 2025 third-quarter report on October 24, 2025. In the first three quarters of 2025, the company achieved an operating revenue of RMB 1.116 billion, representing a year-on-year (YOY) increase of 18.80%. Net profit attributable to the parent company reached RMB 399 million, marking a substantial YOY growth of 71.15%.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44590#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44590"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44590#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2706.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2706.webp","width":1080,"height":608,"caption":"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&D Programs"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44590#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&amp;D Programs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2706.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44590"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44590\/revisions"}],"predecessor-version":[{"id":44594,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44590\/revisions\/44594"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44593"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}